| ORUKA THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US6876041087 / A3DPH3 |
| HQ1 (Frankfurt) / ORKA (NASDAQ) |
| FRA:HQ1, ETR:HQ1, HQ1:GR, NASDAQ:ORKA |
| - |
| https://orukatx.com/ |
|
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleuk..
>Volltext.. |
| 2863.15 Mio. EUR |
| 2581.23 Mio. EUR |
| - |
| -104.06 Mio. EUR |
| -89.95 Mio. EUR |
| -1.98 EUR |
| 1.65 Mio. EUR |
| 40.04 Mio. EUR |
| -75.26 Mio. EUR |
| 21.92 |
| - |
| -57.26% |
| - |
| - |
| - |
| ORUKA |
| 27.04.26 |